Mesoblast Finally Gets FDA Nod For Ryoncil

The cell therapy won approval for pediatric steroid-refractory acute graft versus host disease after two complete response letters over the last four years.

gvhd concept words isometric 3d word text concept with some related text and dot connected - vector
• Source: Shutterstock

Mesoblast plans to immediately start onboarding transplant centers following the US Food and Drug Administration approval of its allogeneic cell therapy Ryoncil (remestemcel-L) for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD), after it was the subject of two complete response letters (CRL) from the agency.

More from Cell Therapies

More from New Products